Abeona Therapeutics Inc.
Abeona Therapeutics Inc. logo
ABEO

Abeona Therapeutics Inc. (ABEO)

$3.761.31%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.595
Day's Range
$3.84
$0.1303
52-Week Range
$6.13
1 month return23.27%
3 month return8.05%
1 year return74.94%
5 year return99.09%

Company Information

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
OrganizationAbeona Therapeutics Inc.
Employees90
CEODr. Vishwas Seshadri M.B.A., Ph.D.
IndustryHealth Technology

Analyst Recommendation

based on 3 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 3 Wall street analysts offering stock ratings for Abeona Therapeutics Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 467.29%

Current

$3.76

Target

$21.33

Recommendation Trend

Based on 3 analyst

Current1M Ago3M Ago
Buy
2
7
7
Hold
1
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
64.1M
Book Value
$2.01
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
38.68
PE Ratio
0.1
PEG Ratio
0.0
Wall Street Target Price
21.33

Valuation

Trailing PE0.1
Forward PE0.0
Price/Book (mrq)
4.25
Enterprise Value
55.6M
Enterprise Value/Revenue
12.79
Enterprise Value/Ebitda
-0.7

Technicals

Beta
1.26
50 Day MA
3.95
200 Day MA
4.88

Institutional Holdings

Adage Capital Partners Gp LLC

4.18%

Vanguard Group Inc

3.81%

AIGH Capital Management, LLC

1.83%

Renaissance Technologies Corp

1.25%

Knoll Capital Management LP

1.16%

Geode Capital Management, LLC

0.47%

Discover more

Frequently Asked Questions

What is Abeona Therapeutics Inc. share price today?

Can Indians buy Abeona Therapeutics Inc. shares?

How can I buy Abeona Therapeutics Inc. shares from India?

Can Fractional shares of Abeona Therapeutics Inc. be purchased?

What are the documents required to start investing in Abeona Therapeutics Inc. stocks?

What are today’s High and Low prices of Abeona Therapeutics Inc.?

What are today’s traded volumes of Abeona Therapeutics Inc.?

What is today’s market capitalisation of Abeona Therapeutics Inc.?

What is the 52 Week High and Low Range of Abeona Therapeutics Inc.?

How much percentage Abeona Therapeutics Inc. is down from its 52 Week High?

How much percentage Abeona Therapeutics Inc. is up from its 52 Week low?

What are the historical returns of Abeona Therapeutics Inc.?

Who is the Chief Executive Officer (CEO) of Abeona Therapeutics Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*